Positive Phase III Data for GSK RSV Vaccine Candidate
A phase III trial investigating the GSK RSV vaccine candidate for adults aged 60 years and above exceeded its primary endpoint with no unexpected safety concerns observed, the company announced.
A phase III trial investigating the GSK RSV vaccine candidate for adults aged 60 years and above exceeded its primary endpoint with no unexpected safety concerns observed, the company announced.
US regulatory advisors are questioning the effectiveness of GlaxoSmithKline’s biologic Nucala as a...
GlaxoSmithKline reported positive results from 2 phase-III clinical trials for mepolizumab, a new treatment for severe eosinophilic asthma. If the drug were to receive FDA approval, it would become the first non-inhaled treatment for severe asthma.